Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology SA (CYAD) announced its participation in several conferences in September 2020, including the Wells Fargo 2020 Virtual Healthcare Conference and the H.C. Wainwright 22nd Annual Global Investment Conference. The company, based in Mont-Saint-Guibert, Belgium, focuses on developing CAR T cell therapies for cancer. Celyad is advancing both allogeneic and autologous therapy candidates for hematological malignancies and solid tumors. The press release includes a forward-looking statement about the expected initiation of a Phase 1 trial by year-end 2020.
Celyad Oncology announced that the FDA has granted permission for the Phase 1 clinical trial of CYAD-211, its first shRNA-based allogeneic CAR T candidate targeting BCMA for relapsed/refractory multiple myeloma. The trial is set to begin by the end of 2020. CYAD-211 is part of the CYAD-200 series and utilizes a unique shRNA technology platform. This marks a significant advancement for Celyad, demonstrating its ability to effectively develop multiple off-the-shelf CAR T therapies.
Celyad SA (Euronext & Nasdaq: CYAD) announced a corporate rebranding to Celyad Oncology, reflecting its commitment to pioneering CAR T cell therapies for cancer. This change accompanies the launch of a new logo and website, aimed at emphasizing the company’s progress in next-generation CAR T programs. CEO Filippo Petti highlighted the firm’s expertise and strategic focus on innovative cell therapies, particularly in the context of recent developments discussed at the American Society of Clinical Oncology conference.
Celyad (CYAD), a clinical-stage biopharmaceutical company, announced its participation in several virtual investor conferences in June 2020. The conferences include: Jefferies Virtual Healthcare Conference from June 2-4, William Blair 40th Annual Growth Stock Conference on June 10 at 2:00 p.m. CDT, and Kepler Cheuvreux Digital Belgian Life Science Day on June 22 at 3:10 p.m. CEST. Celyad is advancing CAR-T cell therapies targeting various cancers, with significant clinical trials ongoing for lead candidates CYAD-01 and CYAD-101.
Celyad (NASDAQ: CYAD) reported operational updates for Q1 2020, highlighting the progression of CAR-T therapies despite COVID-19 challenges. The company initiated the Phase 1 CYCLE-1 trial for CYAD-02 targeting relapsed/refractory AML and MDS. With a treasury of €33.8 million, Celyad expects sufficient funds to support operations through mid-2021. Key milestones include data announcements for CYAD-101 at the ASCO Virtual Scientific Program and the IND application filing for CYAD-211. Preliminary data from trials show promising early signs of clinical activity.
Celyad, a clinical-stage biopharmaceutical company focused on CAR-T therapies, announced the appointments of Dr. Maria Koehler and Mr. Dominic Piscitelli to its Board of Directors, effective March 24 and May 6, 2020. Dr. Koehler, with over 20 years in oncology drug development, and Mr. Piscitelli, who has extensive experience in financial operations, will enhance Celyad's strategic and operational capabilities. The company is advancing its CAR-T therapies, including CYAD-01, in various clinical trials to treat hematological malignancies and solid tumors.
Summary not available.